Dupilumab Shows Promise for Eosinophilic Gastritis in First-of-Its-Kind Study
August 6, 2026 | 1 min. read
A new multisite study is the first to demonstrate that dupilumab improves clinical and histologic outcomes in patients with eosinophilic gastritis (EoG), which currently has no FDA-approved treatments. The clinical trial was conducted by the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) within the National Institutes of Health’s Rare Diseases Clinical Research Network, in collaboration with Northwestern Medicine.
How the study evaluated efficacy Building on the success of dupilumab in eosinophilic esophagitis, investigators explored its efficacy in EoG. To do so, the team leveraged outcome measures developed through CEGIR’s OMEGA study, which advanced clinical trial readiness in rare GI diseases.
In the randomized, placebo-controlled study, 41 patients with EoG received dupilumab or placebo over 12 weeks. Dupilumab met the primary endpoint and significantly improved secondary measures, including gastric eosinophil counts, endoscopic findings, histologic features and molecular biomarkers. Nirmala Gonsalves, MD, was co-lead of this study and a CEGIR site principal investigator.
Takeaways The findings:
Reinforce that EoG, a rare gastrointestinal disorder, is driven by type 2 inflammation.
Suggest that targeting this pathway can meaningfully alter disease activity.
Support consideration of off-label use.
Lay the groundwork for larger trials aimed at regulatory approval.
“This represents a major unmet need for patients,” says Dr. Gonsalves. “Treatment approaches to date have relied on limited evidence and expert opinion. This study provided insights into disease mechanisms and is a first step in improving the lives of patients with these debilitating diseases.”